A vast phase III clinical trial in Africa of the malaria vaccine candidate RTS,S/AS01 reported disappointing results this morning. The vaccine failed to show substantial protection in the key trial age group of infants who received their first shot between 6 and 12 weeks of age. The low protective effect of the vaccine was around half that reported last year in older children in the same study, and that of an earlier, smaller trial of babies of the same age group.
Click "source" to read more.
